Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pippa Corrie

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trialSomnath Mukherjee, Cathy Qi, Rachel Shaw, et al.
Nature Communications|August 29, 2020
Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastasesRoy Rabbie, Naser Ansari-Pour, Oliver Cast, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP StudyJohn Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
The Lancet. Oncology|March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyJohn N Primrose, Richard P Fox, Daniel H Palmer, et al.
Nature Communications|February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.
Developmental Cell|September 16, 2021
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formationNathaniel R Campbell, Anjali Rao, Miranda V Hunter, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trialSomnath Mukherjee, Cathy Qi, Rachel Shaw, et al.
Nature Communications|August 29, 2020
Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastasesRoy Rabbie, Naser Ansari-Pour, Oliver Cast, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP StudyJohn Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
The Lancet. Oncology|March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyJohn N Primrose, Richard P Fox, Daniel H Palmer, et al.
Nature Communications|February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.
Developmental Cell|September 16, 2021
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formationNathaniel R Campbell, Anjali Rao, Miranda V Hunter, et al.
Pageof 6